Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2395-2404

  Morrison, Alan ^a,c   Ramey, Dena Rosen ^b   Van Adelsberg, Janet ^b   Watson, Douglas J ^b  

^a SRIBCO   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c SCRIBCO   (United States)

Author keywords

Anti inflammatory agents, non steroidal; Blood pressure; Hypertension; Pooled analysis; Randomized controlled trials

Indexed keywords

DICLOFENAC; DIFLUNISAL; ETODOLAC; FENOPROFEN; FLOCTAFENINE; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PHENYLBUTAZONE; PIROXICAM; PLACEBO; SULINDAC; TENOXICAM; TIAPROFENIC ACID; TOLMETIN;

ALZHEIMER DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HUMAN; HYPERTENSION; META ANALYSIS; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; HUMANS; HYPERTENSION; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 35648968141     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219553     Document Type: Conference Paper

References (51)

1. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors. J Intern Med 2003;253:643-52
2. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension 2004;43:525-30
3. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15
4. Ofman JJ, MacLean CH, Straus WL, Morton SC, et al. A meta-analysis of severe upper gastrointestinal complications of non-steroidal antiinflammatory drugs. J Rheumatol 2002;29:804-12
5. Rostom A, Dube C, Wells G, Tugwell P, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002.CD002296
6. Ofman JJ, Maclean CH, Straus WL, Morton SC, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003;49:508-18
7. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005;165:490-6
8. Matchaba P, Gitton X, Krammer G, Ehrsam E, et al. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or = 1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis. Clin Ther 2005;27:1196-214
9. Moore RA, Deny S, Makinson GT, McQuay HJ. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005;7:R644-65
10. Kearney PM, Baigent C, Godwin J, Halls H, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-8
11. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006;296:1619-32
12. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-84
13. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300
14. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325:619
15. Garner SE, Fidan DD, Frankish R, Maxwell L. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005:CD005115
16. Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev 2004: CD000189
17. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26
18. Bhagat K. Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. East Afr Med J 2001;78: 507-9
19. Collantes E, Curtis SP, Lee KW, Casas N, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract 2002;3:10
20. Ebel DL, Rhymer AR, Stahl E, Tipping R. Effect of Clinoril (sulindac, MSD), piroxicam and placebo on the hypotensive effect of propranolol in patients with mild to moderate essential hypertension. Scand J Rheumatol Suppl 1986;62:41-9
21. Emery P, Zeidler H, Kvien TK, Guslandi M, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11
22. Gertz BJ, Krupa D, Bolognese JA, Sperling RS, et al. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin 2002;18:82-91
23. Geusens P, Alten R, Rovensky J, Sloan VS, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract 2004;58:1033-41
24. Goldberg MA. A multicenter study of the safety and efficacy of naproxen: analysis of blood pressure. Semin Arthritis Rheum 1988;17:23-8
25. Gurwitz JH, Everitt DE, Monane M, Glynn RJ, et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996;51:M74-9
26. Harvey PJ, Wing LM, Beilby J, Ramsay A, et al. Effect of indomethacin on blood pressure control during treatment with nitrendipine. Blood Press 1995;4:307-12
27. Hawkey CJ, Laine L, Simon T, Quan H, et al. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003;52:820-6
28. Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, et al. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc 2004;52:666-74
29. Klassen D, Goodfriend TL, Schuna AA, Young DY, et al. Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. J Clin Pharmacol 1993;33:971-8
30. Klassen DK, Jane LH, Young DY, Peterson CA. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens 1995;8: 146-53
31. Koopmans PP, Thien T, Gribnau FW. The influence of ibuprofen, diclofenac and sulindac on the blood pressure lowering effect of hydrochlorothiazide. Eur J Clin Pharmacol 1987;31:553-7
32. Koopmans PP, Thien T, Gribnau FW. Influence of non-steroidal anti-inflammatory drugs on diuretic treatment of mild to moderate essential hypertension. Br Med J (Clin Res Ed) 1984;289:1492-4
33. Koopmans PP, Thien T, Thomas CM, Van den Berg RJ, et al. The effects of sulindac and indomethacin on the anti-hypertensive and diuretic action of hydrochlorothiazide in patients with mild to moderate essential hypertension. Br J Clin Pharmacol 1986;21:417-23
34. Lisse JR, Perlman M, Johansson G, Shoemaker JR, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003;139:539-46
35. Lohmander LS, McKeith D, Svensson O, Malmenas M, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005;64:449-56
36. Lucker PW, Pawlowski C, Friedrich I, Faiella F, et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm 1994;14:29-38
37. Matsumoto AK, Melian A, Mandel DR, McIlwain HH, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29: 1623-30
38. Murray MD, Lazaridis EN, Brizendine E, Haag K, et al. The effect of nonsteroidal antiinflammatory drugs on electrolyte homeostasis and blood pressure in young and elderly persons with and without renal insufficiency. Am J Med Sci 1997;314:80-8
39. Oparil S, Horton R, Wilkins LH, Irvin J, et al. Antihypertensive effect of enalapril in essential hypertension: role of prostacyclin. Am J Med Sci 1987;294:395-402
40. Palmer R, Weiss R, Zusman RM, Haig A, et al. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003;16:135-9
41. Puddey IB, Beilin LJ, Vandongen R, Banks R, et al. Differential effects of sulindac and indomethacin on blood pressure in treated essential hypertensive subjects. Clin Sci (Lond) 1985;69: 327-36
42. Schwartz JI, Vandormael K, Malice MP, Kalyani RN, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002;72:50-61
43. Schnitzer TJ, Gitton X, Jayawardene S, Sloan VS. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. Curr Med Res Opin 2005;21:151-61
44. Smith MD, Kupa A, Weatherall M, Henstridge JD, et al. The effect of tiaprofenic acid on blood pressure control in treated hypertensive patients. Curr Med Res Opin 1985;9:388-93
45. Thakur V, Cook ME, Wallin JD. Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal antiinflammatory drugs. Am J Hypertens 1999;12:925-8
46. Truitt KE, Sperling RS, Ettinger WH, Jr, Greenwald M, et al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 2001;13:112-21
47. White WB, Faich G, Whelton A, Maurath C, et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-30
48. Wong DG, Spence JD, Lamki L, Freeman D, et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986;1:997-1001
49. Sowers JR, White WB, Pitt B, Whelton A, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8
50. Izhar M, Alausa T, Folker A, Hung E, et al. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004;43:573-7
51. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis. Methods for quantitatitive synthesis in medicine. In Monographs in Epidemiology and Biostatistics, Vol 24. New York: Oxford University Press, 1994